Patents by Inventor ROBERTO IACONE

ROBERTO IACONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CLAUDIN-1 MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF FIBROTIC DISEASES
    Publication number: 20230138047
    Abstract: The present invention concerns the use of anti-Claudin-1 monoclonal antibodies, and pharmaceutical compositions thereof, for the prevention and/or treatment of a fibrotic disease in a patient, in particular pulmonary fibrosis, kidney fibrosis or skin fibrosis. Methods of preventing and/or treating pulmonary fibrosis kidney fibrosis or skin fibrosis by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 4, 2023
    Inventors: Thomas Baumert, Emilie CROUCHET, Roberto IACONE, Markus MEYER, Natascha ROHLEN, Antonio SAVIANO, Catherine SCHUSTER, Tamas SCHWEIGHOFFER
  • Modified IL-2 polypeptides and uses thereof
    Patent number: 11633488
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: April 25, 2023
    Assignee: Bright Peak Therapeutics AG
    Inventors: Vijaya Raghavan Pattabiraman, Roberto Iacone, Jean-Philippe Carralot, Matilde Arévalo-Ruiz, Jeffrey William Bode, Alexander Mayweg, Fränzi Weibel, Anna Haydn, Régis Boehringer, Görkem Kurtuldu Sahin, Claudia Fetz, Camille Delon, Eric Armentani, Alexander Flohr, Giorgio Ottaviani
  • MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF
    Publication number: 20220056091
    Abstract: The present disclosure relates to modified IL-18 polypeptides, compositions comprising modified IL-18 polypeptides, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-18 polypeptides. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN?. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN? without being neutralized by IL-18 binding protein.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 24, 2022
    Inventors: Vijaya Raghavan PATTABIRAMAN, Jean-Philippe CARRALOT, Bertolt KREFT, Jeffrey William BODE, Régis BOEHRINGER, Matilde ARÉVALO-RUIZ, Camille DELON, Amélie WIEDERKEHR, Claudia FETZ, Anna HAYDN, Alexander FLOHR, Roberto IACONE, Benoit HORNSPERGER, Chongqing WANG
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20220042022
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 10, 2022
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF
    Publication number: 20210252157
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Vijaya Raghavan PATTABIRAMAN, Roberto IACONE, Jean-Philippe CARRALOT, Matilde ARÉVALO-RUIZ, Jeffrey William BODE, Alexander MAYWEG, Fränzi WEIBEL, Anna HAYDN, Régis BOEHRINGER, Görkem KURTULDU SAHIN, Claudia FETZ, Camille DELON, Eric ARMENTANI, Alexander FLOHR, Giorgio OTTAVIANI
  • Difluoroketamide derivatives as HtrA1 inhibitors
    Patent number: 11059858
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: July 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hans P. Maerki, Benoit Hornsperger, Peter Mohr, Michael Reutlinger, Roberto Iacone
  • Trifluoromethylpropanamide derivatives as HTRA1 inhibitors
    Patent number: 11014963
    Abstract: The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R3, R8, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 25, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200399641
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: December 30, 2019
    Publication date: December 24, 2020
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • COMPANION DIAGNOSTIC FOR HTRA1 RNA ANTAGONISTS
    Publication number: 20200378970
    Abstract: The present invention relates to the use of HTRA1 mRNA antagonists in the treatment of eye disorders, such as macular degeneration, and the use of an HTRA1 levels in the aqueous and vitreous humor as a diagnostic biomarker for the suitability of treatment of a subject with an HTRA1 mRNA antagonist.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 3, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Jakob, Jean-Luc Mary, Heidi Rye Hudlebusch, Thomas Peter John Dunkley, Corinne Stucki, Ulrich Friedrich Oskar Luhmann, Carolin Rakebrandt
  • Small molecule based conversion of somatic cells into neural crest cells
    Patent number: 10724000
    Abstract: This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions. Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Graf, Roberto Iacone, Eva Christina Thoma
  • METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO VASCULAR BED CELLS
    Publication number: 20200182861
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions.
    Type: Application
    Filed: September 5, 2019
    Publication date: June 11, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Klaus Christensen, Martin Graf, Roberto Iacone, Christoph Patsch, Eva Christina Thoma
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200157546
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • Antisense oligonucleotides for modulating HTRA1 expression
    Patent number: 10519450
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • Difluoroketamide derivatives
    Patent number: 10428108
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 1, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Eric A. Kitas, Hans P. Maerki, Michael Reutlinger, Peter Mohr
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20190055564
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: May 29, 2018
    Publication date: February 21, 2019
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20180371015
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans P. Maerki, Benoit Hornsperger, Peter Mohr, Michael Reutlinger, Roberto Iacone
  • TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20180371016
    Abstract: The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R3, R8, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • Method for differentiation of pluripotent stem cells into multi-competent renal precursors
    Patent number: 10138468
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 27, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jacques Bailly, Osele Ciampi, Martin Graf, Roberto Iacone, Christoph Patsch
  • Trifluoromethylpropanamide derivatives
    Patent number: 9980929
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 29, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Bernd Kuhn, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • NEW DIFLUOROKETAMIDE DERIVATIVES
    Publication number: 20180057526
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benoit HORNSPERGER, Roberto IACONE, Eric A. KITAS, Hans P. MAERKI, Michael REUTLINGER, Peter MOHR